• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    6/6/24 8:07:48 AM ET
    $AEMD
    $CCM
    $CERO
    $DBVT
    Medical/Dental Instruments
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $AEMD alert in real time by email

    Gainers

    • Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 124.3% to $0.98 during Thursday's pre-market session. The company's market cap stands at $4.9 million.
    • Virax Biolabs Group (NASDAQ:VRAX) stock increased by 116.82% to $2.32. The company's market cap stands at $5.4 million.
    • iSpecimen (NASDAQ:ISPC) shares increased by 36.65% to $0.44. The market value of their outstanding shares is at $4.3 million.
    • 60 Degrees (NASDAQ:SXTP) shares moved upwards by 28.26% to $0.37. The company's market cap stands at $4.4 million.
    • CERo Therapeutics Hldgs (NASDAQ:CERO) shares rose 27.08% to $1.15. The market value of their outstanding shares is at $17.3 million.
    • OneMedNet (NASDAQ:ONMD) stock increased by 24.99% to $2.0. The market value of their outstanding shares is at $47.7 million.

    Losers

    • Fresh2 Group (NASDAQ:FRES) shares decreased by 18.3% to $0.49 during Thursday's pre-market session. The company's market cap stands at $12.1 million.
    • Renalytix (NASDAQ:RNLX) stock fell 15.93% to $0.39. The market value of their outstanding shares is at $30.2 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) shares fell 14.98% to $0.12. The company's market cap stands at $1.2 million.
    • Concord Medical Services (NYSE:CCM) stock fell 13.28% to $0.98. The market value of their outstanding shares is at $42.5 million.
    • Masimo (NASDAQ:MASI) shares fell 9.98% to $112.19. The company's market cap stands at $5.9 billion.
    • DBV Technologies (NASDAQ:DBVT) shares decreased by 8.61% to $0.53. The market value of their outstanding shares is at $101.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $CCM
    $CERO
    $DBVT

    CompanyDatePrice TargetRatingAnalyst
    DBV Technologies S.A.
    $DBVT
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    DBV Technologies S.A.
    $DBVT
    12/3/2025$35.00Buy
    Guggenheim
    Masimo Corporation
    $MASI
    11/17/2025Neutral
    BofA Securities
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    CERo Therapeutics Holdings Inc.
    $CERO
    6/23/2025$30.00Hold → Buy
    D. Boral Capital
    DBV Technologies S.A.
    $DBVT
    5/29/2025$7.25Sell
    Goldman
    Virax Biolabs Group Limited
    $VRAX
    3/31/2025$3.00Buy
    H.C. Wainwright
    Masimo Corporation
    $MASI
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    More analyst ratings

    $AEMD
    $CCM
    $CERO
    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AEMD
    $CCM
    $CERO
    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

    MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet's position for life sciences and healthcare organizations generati

    2/27/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a digital health company specializing in autoimmune disease populations. This partnership expands OneMedNet's autoimmune clinical ontology, to the OneMedNet iRWD™ platform—powered by Palantir Foundry—further increasing the scale, diversity, and longitudinal depth of its regulatory-grade Real-World Data. Under the agreement, ViuHealth will provide ongoing, longitudinal autoimmune disease data, strengthening OneMedNet's portfolio of high-value specialty datasets and supporting resea

    2/26/26 8:40:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

    Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device's robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of ad

    2/26/26 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEMD
    $CCM
    $CERO
    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Young Micah W was granted 2,034 shares and covered exercise/tax liability with 1,123 shares, increasing direct ownership by 5% to 18,347 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    2/26/26 8:13:18 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CEO Szyman Catherine M. exercised 11,141 shares at a strike of $132.96 and covered exercise/tax liability with 4,568 shares (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    2/13/26 5:28:49 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Medical Officer Mohideen Pharis sold $2,595 worth of Ordinary Shares (534 units at $4.86), decreasing direct ownership by 0.37% to 144,995 units (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    2/2/26 4:30:20 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $CCM
    $CERO
    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Masimo

    BofA Securities initiated coverage of Masimo with a rating of Neutral

    11/17/25 9:40:41 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEMD
    $CCM
    $CERO
    $DBVT
    SEC Filings

    View All

    SEC Form DFAN14A filed by Masimo Corporation

    DFAN14A - MASIMO CORP (0000937556) (Subject)

    2/27/26 4:15:15 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    iSpecimen Inc. filed SEC Form 8-K: Leadership Update

    8-K - iSpecimen Inc. (0001558569) (Filer)

    2/23/26 4:30:12 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Aethlon Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    2/23/26 4:15:32 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $CCM
    $CERO
    $DBVT
    Leadership Updates

    Live Leadership Updates

    View All

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AEMD
    $CCM
    $CERO
    $DBVT
    Financials

    Live finance-specific insights

    View All

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26

    Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call or the webcast, please use the link below. Upon registering, each participant will be provided with details for the call or webcast. Conference Call Registration Link (Please register to obtain the dial-in number): Masim

    2/12/26 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEMD
    $CCM
    $CERO
    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

    SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    12/13/24 7:18:17 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by CERo Therapeutics Holdings Inc.

    SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    11/20/24 4:06:55 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

    SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    11/20/24 4:01:41 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care